2017-2018 Hematology Drug Approvals at the Food and Drug Administration (FDA): Communication of Patient-Reported Outcomes (PRO) Information in FDA Clinical Reviews and Prescribing Information (PI)

医学 临床试验 临床研究 血液学 标签外使用 食品药品监督管理局 内科学 新药申请 机构审查委员会 家庭医学 药理学 外科
作者
Janice Kim,Bindu Kanapuru,Jessica Roydhouse,Ann T. Farrell,Najat Bouchkouj,Hussein Ezzeldin,Paul G. Kluetz
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 3450-3450 被引量:3
标识
DOI:10.1182/blood-2019-125798
摘要

Introduction: In recent years, there has been increased interest in patient experience data, including PROs. To determine how and where PRO data are being assessed and communicated as part of approval of a marketing application, we examined approvals in the Center of Drugs Evaluation and Research in the Office of Hematology and Oncology Products as well as the Center for Biologics Evaluation and Research. Here we report on PRO data from malignant and benign hematology indications. Method: New Molecular Entity (NME) and Supplemental applications with new indications approved between 2017 and 2018 were examined. We reviewed sponsor's clinical study reports (CSRs) for inclusion of PRO data. We assessed FDA review of this data by determining how often PRO data were incorporated in the Prescribing Information (label) and/or final FDA Clinical Reviews. Results: From 2017 to 2018 a total of 31 NMEs and 33 supplemental applications were approved for benign and malignant hematology indications (Figure 1). Of the 10 benign hematology NMEs and BLAs approved, 3 (30%) contained PRO data in the sponsor's CSR, and FDA included the PRO data in all three FDA clinical reviews with one application (Emicizumab) having PRO data incorporated in the FDA product labeling. Emicizumab's label captured disease symptoms and physical functioning, prespecified secondary endpoints in the trial. Of the 15 malignant hematology NMEs and BLAs approved, 7 (47%) contained PRO data in the sponsor's CSR. Of the 7 submissions that contained PRO data, 6 (86%) included PRO data in the FDA clinical review and PRO data were incorporated into the label for one application. Rituxan Hycela's label captured patient preference supported by a large randomized clinical trial with preference as the primary objective. Of the 8 supplemental indications for benign hematology, 3 (38%) of the applications contained PRO data in the sponsor's CSR and FDA included the PRO in all three FDA clinical reviews with one application (Feraheme) having PRO data incorporated in the FDA product labeling. Feraheme captured descriptive disease symptom data. Of the 20 applications submitted for supplemental indications for hematologic malignancies, 13 (65%) contained PRO data in the sponsor's CSR. Twelve of the 13 applications that contained PRO data (92%) had this data discussed in the FDA clinical review, and one application (ibrutinib) incorporated PRO data in FDA product labeling. Ibrutinib captured descriptive disease symptom data. Discussion: When PRO data were included in efficacy submissions to FDA, a large portion of FDA clinical reviews included discussion of this information. PRO data were included in the label more frequently for benign indications compared to malignant indications. When in the label, PRO data tended to refer to disease symptoms and physical function, both of which have been specified as being part of FDA's proposed core outcome set for cancer. Figure 1 Disclosures No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
孤独士晋完成签到,获得积分10
刚刚
自信的冬日完成签到,获得积分10
1秒前
超帅发夹完成签到 ,获得积分10
1秒前
year完成签到 ,获得积分10
3秒前
丁莞完成签到,获得积分10
3秒前
李月完成签到,获得积分10
4秒前
li完成签到,获得积分10
4秒前
Gcia完成签到,获得积分10
4秒前
4秒前
musicyy222完成签到,获得积分10
5秒前
科研通AI6.3的应助被Moonber采纳,获得10
5秒前
candy7c完成签到 ,获得积分10
5秒前
7秒前
CodeCraft的应助被科研通管家采纳,获得10
7秒前
小马甲的应助被科研通管家采纳,获得10
8秒前
在水一方的应助被呆萌的源智采纳,获得10
8秒前
852的应助被科研通管家采纳,获得10
8秒前
8秒前
CAOHOU的应助被科研通管家采纳,获得10
8秒前
Maestro_S的应助被科研通管家采纳,获得10
8秒前
Maestro_S的应助被科研通管家采纳,获得10
8秒前
Jasper的应助被科研通管家采纳,获得10
8秒前
无花果的应助被科研通管家采纳,获得10
8秒前
9秒前
Hello的应助被科研通管家采纳,获得10
9秒前
小蘑菇的应助被科研通管家采纳,获得10
9秒前
9秒前
bl完成签到,获得积分10
9秒前
墨末完成签到,获得积分10
10秒前
朴实的绮兰完成签到 ,获得积分10
10秒前
30完成签到 ,获得积分10
11秒前
旋风0127发布了新的文献求助10
11秒前
鱼憨儿完成签到,获得积分10
12秒前
12秒前
碎冰蓝完成签到 ,获得积分10
14秒前
任性冥王星完成签到 ,获得积分10
15秒前
NexusExplorer的应助被小郭采纳,获得10
16秒前
Moonber完成签到,获得积分10
17秒前
houniao发布了新的文献求助10
18秒前
feng完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185571
求助须知:如何正确求助?哪些是违规求助? 9574336
关于积分的说明 21835187
捐赠科研通 7783367
什么是DOI,文献DOI怎么找? 3434606
关于科研通互助平台的介绍 2558985
邀请新用户注册赠送积分活动 2481374